June 2019 in “Journal of Drug Delivery and Therapeutics” This review highlights the use of finasteride, a 5alpha-reductase inhibitor, for treating benign prostatic hyperplasia and male pattern hair loss, noting that it may cause male sexual dysfunction but usually with tolerable side effects that decrease over time, not requiring treatment discontinuation.
3 citations
,
April 2019 in “Human & Experimental Toxicology” This study found that finasteride caused adverse effects on liver, kidney, and heart tissues in female mice, raising concerns about its potential use in females for treating androgenetic alopecia.
January 2015 in “프로그램북(구 초록집)” This article reviews the impact of dutasteride on hair growth in androgenetic alopecia, finding it significantly increases hair count and width compared to finasteride and placebo, but reports no new results.
2 citations
,
September 2009 in “Hormone Molecular Biology and Clinical Investigation” This study found that low-dose finasteride treatment in men with premature androgenetic alopecia decreased levels of 5α-reduced steroids, which may be linked to increased depression symptoms.
9 citations
,
January 2009 in “PubMed” This study found that finasteride treatment in men with benign prostate hyperplasia significantly altered steroid hormone profiles and may contribute to depressive symptoms by affecting neuroactive steroid levels.
4 citations
,
September 2006 in “European Urology Supplements” Dutasteride reduces DHT and improves BPH symptoms more effectively than finasteride.
72 citations
,
January 2004 in “Dermatology” This study found that oral finasteride, at a dosage of 2.5 mg/day or more, may improve hair growth and appearance in postmenopausal women with pattern hair loss, without adverse effects.
41 citations
,
July 2001 in “PubMed” This study reported that while finasteride and progesterone significantly inhibited dihydrotestosterone synthesis in dermal papillae, estrogens were less effective.
June 2001 in “International Journal of Cosmetic Surgery and Aesthetic Dermatology” This review discusses advances in 5α-reductase inhibitors for treating male androgenetic alopecia and reports no new clinical results.
15 citations
,
January 1998 in “Journal of Clinical Periodontology” Finasteride helps treat hair loss by blocking enzyme activity.
7 citations
,
September 1997 in “PubMed” This study found that Finasteride treatment significantly reduced dihydrotestosterone and epidermal growth factor levels in benign prostatic hyperplasia tissue, particularly in the periurethral zone, while Flutamide decreased epidermal growth factor but not dihydrotestosterone.
3 citations
,
June 1996 in “PubMed” This review discusses the effects and potential benefits of finasteride in treating hirsutism and androgenetic alopecia but reports no new clinical results.
93 citations
,
January 1996 in “Clinical Pharmacokinectics” Finasteride helps regrow hair and shrink prostate by reducing DHT, with some sexual side effects.
12 citations
,
January 1993 in “PubMed” This review discusses the pharmacology and clinical use of finasteride for benign prostatic hyperplasia and reports its effectiveness in reducing prostate size and symptoms, though success varies among patients.